Deutsche Bank’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-879
Closed -$60K 4410
2022
Q1
$60K Sell
879
-421
-32% -$35K ﹤0.01% 3780
2021
Q4
$158K Sell
1,300
-548
-30% -$92.5K ﹤0.01% 3493
2021
Q3
$260K Buy
1,848
+832
+82% +$165K ﹤0.01% 3426
2021
Q2
$280K Buy
1,016
+176
+21% +$44.4K ﹤0.01% 3589
2021
Q1
$180K Buy
840
+24
+3% +$6.63K ﹤0.01% 3693
2020
Q4
$198K Buy
816
+250
+44% +$30.9K ﹤0.01% 3473
2020
Q3
$60K Buy
566
+179
+46% +$16.3K ﹤0.01% 3793
2020
Q2
$38K Buy
387
+161
+71% +$14.1K ﹤0.01% 3931
2020
Q1
$16K Sell
226
-132
-37% -$12.6K ﹤0.01% 3973
2019
Q4
$28K Buy
358
+172
+92% +$19.2K ﹤0.01% 4199
2019
Q3
$21K Sell
186
-391
-68% -$53.8K ﹤0.01% 4310
2019
Q2
$102K Sell
577
-340
-37% -$55K ﹤0.01% 4201
2019
Q1
$145K Buy
917
+15
+2% +$2.97K ﹤0.01% 4171
2018
Q4
$234K Buy
902
+294
+48% +$59.2K ﹤0.01% 3794
2018
Q3
$148K Buy
608
+94
+18% +$24.6K ﹤0.01% 4356
2018
Q2
$121K Buy
+514
New +$150K ﹤0.01% 4477

Other funds holding EVLO

Deutsche Bank's EVLO Position: Q2 2022 in Review

Deutsche Bank sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 879 shares — an estimated $60K sold.

Deutsche Bank first reported a position in EVLO in Q2 2018 and held it in 16 quarters. The position peaked at $280K in Q2 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • Deutsche Bank reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 879 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $60K.
  • Deutsche Bank first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
  • Deutsche Bank's Evelo Biosciences, Inc. Common Stock position peaked at $280K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.